Intravitreal Bevacizumab in acute Branch Retinal Vein Occlusion(BRVO)
Phase 2
- Conditions
- Branch Retinal Vein occlusion.Other retinal vascular occlusions
- Registration Number
- IRCT201106214856N2
- Lead Sponsor
- Vice chancellor for research, Baqiyatallah University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Inclusion: Patients with initial diagnose of branch retinal vein occlusion(BRVO) based on examination with Slit Lamp; Less than one week of symptoms onset.
Exclusion: Other pathologies of retinal vessels beside BRVO based on flurcein angiography(FA); Patients that have recevied any medication for BRVO.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Macular Thickness. Timepoint: Befor injection and 1,3 and 6 to 16 monthes after injection. Method of measurement: Optical Coherence Tomography(OCT).
- Secondary Outcome Measures
Name Time Method Visual accuity. Timepoint: Before injection and 1,3 and 6 to 16 monthes after injection. Method of measurement: Snelen Chart.